K 
Kiniksa Pharmaceuticals International KNSA · USD
Health Care · US listing · 🇺🇸 United States
98.76
+5.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in USD, from our data supplier.
Revenue
$677.6m
FY2016FY2025
Net income
$59.0m
FY2016FY2025
Free cash flow
$25.4m
FY2016FY2025
Shareholders' equity
$567.6m
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $677.6m | $423.2m | $270.3m | $220.2m | $38.5m | $7.7m | — | — | — | — |
| Research and development | $96.9m | $111.6m | $76.1m | $65.5m | $99.3m | $112.0m | $135.0m | $86.6m | $56.4m | $17.4m |
| Operating income | $77.2m | −$45.6m | −$25.2m | $9.8m | −$156.6m | −$157.4m | −$170.0m | −$108.2m | −$65.4m | −$24.0m |
| Net income | $59.0m | −$43.2m | $14.1m | $183.4m | −$157.9m | −$161.4m | −$161.9m | −$103.2m | −$64.9m | −$24.0m |
| Diluted earnings per share | 0.75 | -0.60 | 0.19 | 2.57 | -2.29 | -2.37 | -2.95 | -2.13 | -2.00 | -0.74 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $763.6m | $580.6m | $526.3m | $459.7m | $232.8m | $349.5m | $254.5m | $322.0m | $47.5m | $56.5m |
| Cash and short-term investments | $414.1m | $243.6m | $206.4m | $190.6m | $182.2m | $323.5m | $233.4m | $307.3m | $45.6m | $56.0m |
| Total liabilities | $196.0m | $142.1m | $87.5m | $63.5m | $47.8m | $37.5m | $29.1m | $42.7m | $137.2m | $82.2m |
| Shareholders' equity | $567.6m | $438.4m | $438.8m | $396.1m | $185.0m | $311.9m | $225.4m | −$194.2m | −$89.7m | −$25.7m |
| Shares outstanding | 79m | 72m | 73m | 71m | 69m | 68m | 55m | 48m | 32m | 32m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | $25.7m | $25.7m | $13.3m | $5.8m | −$126.3m | −$136.5m | −$158.4m | −$81.0m | −$50.2m | −$21.9m |
| Capital spending | −$277,000 | −$277,000 | −$130,000 | −$105,000 | −$20.4m | −$283,000 | −$3.2m | −$5.3m | −$69,000 | −$3,000 |
| Free cash flow | $25.4m | $25.4m | $13.2m | $5.7m | −$146.7m | −$136.8m | −$161.6m | −$86.3m | −$50.3m | −$21.9m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $243.6m | $214.3m | $202.1m | $180.9m | $156.8m | $137.8m | $122.5m | $112.2m |
| Operating income | $27.2m | $29.3m | $19.8m | $24.0m | $20.2m | $13.3m | −$19.3m | −$9.7m |
| Net income | $25.4m | $22.6m | $14.2m | $18.4m | $17.8m | $8.5m | −$8.9m | −$12.7m |
| Diluted earnings per share | 0.30 | 0.27 | 0.18 | 0.23 | 0.23 | 0.11 | -0.12 | -0.18 |
| Cash from operations | $47.0m | $50.0m | $53.0m | $33.0m | $28.0m | $22.0m | $18.0m | −$2.0m |
| Total assets | $896.1m | $825.3m | $763.6m | $712.3m | $661.1m | $599.3m | $580.6m | $555.3m |
| Cash and short-term investments | $525.9m | $468.1m | $414.1m | $352.1m | $307.8m | $268.3m | $243.6m | $223.8m |
| Debt | $4.0m | $3.2m | $3.0m | $2.7m | $2.5m | $2.3m | $2.0m | $2.0m |
| Shareholders' equity | $654.1m | $605.7m | $567.6m | $535.4m | $495.0m | $457.5m | $438.4m | $437.0m |
Financial ratios
Data as of 22 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|
| Operating margin | 13.1% | -8.5% | -6.2% | 5.0% | -406.4% | -2042.6% | — |
| Net margin | 8.7% | -10.2% | 5.2% | 83.3% | -409.7% | -2094.8% | — |
| Return on equity | 10.4% | -9.9% | 3.2% | 46.3% | -85.3% | -51.7% | — |
| Return on assets | 7.7% | -7.4% | 2.7% | 39.9% | -67.8% | -46.2% | — |
| Free cash flow yield | 0.4% | 0.5% | 0.2% | 0.1% | -1.9% | -2.5% | — |
| Revenue growth | 60.1% | 56.6% | 22.7% | 471.2% | 400.3% | — | — |
| Earnings growth | -236.6% | -406.7% | -92.3% | -216.1% | -2.1% | -0.3% | — |
| Current ratio | 3.79x | 3.30x | 4.34x | 5.16x | 4.38x | 10.46x | — |
| Debt to equity | 0.01x | 0.00x | 0.01x | 0.01x | 0.02x | 0.01x | — |
| Equity ratio | 74.3% | 75.5% | 83.4% | 86.2% | 79.5% | 89.3% | — |
| Interest coverage | — | — | — | 8.80x | -63.88x | -44.47x | -20.94x |
| R&D as a share of sales | 14.3% | 26.4% | 28.2% | 29.7% | 257.6% | 1454.3% | — |
| Buybacks as a share of market value | -9.2% | 0.5% | -1.8% | -3.5% | -1.3% | -24.0% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 45.5% | 144.8% | — |
| Operating income | 99.2% | — | — |
| Net income | -31.5% | — | — |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Price to earnings | 55.2 | -33.1 | 90.5 | 5.8 | -5.1 | -7.5 | -3.8 | -13.2 |
| Price to sales | 4.8 | 3.4 | 4.7 | 4.9 | 21.1 | 156.1 | — | — |
Market value over time
31 May 2018 to 21 Oct 2026, in USD
$34.2m$6.65bn
Share price return
Finished calendar years
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Return | 109% | 5% | 29% | 12% | -32% | 57% | -40% | 8% |
Dividends and splits
Per share, in the currency the company pays
Paid for 0 years.
- 1-to-1 reverse split · 28 Jun 2024
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.